Lars Nieba
Chief Executive Officer chez Engimmune Therapeutics AG
Fortune : 1 564 $ au 31/03/2024
Profil
Lars Nieba is currently the Chief Executive Officer at Engimmune Therapeutics AG.
Previously, he worked as the Vice President at Bayer AG from 2016 to 2019.
He also served as the Chief Executive & Technology Officer at Nordic Nanovector ASA from 2020 to 2021.
Dr. Nieba was a Venture Partner at Pureos Partners AG from 2021 to 2023.
In terms of education, he holds a doctorate from the Max Planck Institute of Biochemistry, a graduate degree from the University of Freiburg (conferred in 1993), an MBA from the University of St. Gallen (conferred in 2003), and another doctorate from the University of Zurich (conferred in 1997).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
THOR MEDICAL ASA
0,01% | 31/12/2022 | 15 713 ( 0,01% ) | 1 564 $ | 31/03/2024 |
Postes actifs de Lars Nieba
| Sociétés | Poste | Début |
|---|---|---|
Engimmune Therapeutics AG
 Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Chief Executive Officer | 19/04/2023 |
Anciens postes connus de Lars Nieba
| Sociétés | Poste | Fin |
|---|---|---|
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Private Equity Investor | 30/04/2023 |
| BAYER AG | Corporate Officer/Principal | 01/11/2019 |
| THOR MEDICAL | Chief Executive Officer | 06/04/2021 |
Formation de Lars Nieba
| University of Freiburg | Graduate Degree |
| University of St. Gallen | Masters Business Admin |
| University of Zurich | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BAYER AG | Health Technology |
| Entreprise privées | 3 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Finance |
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Technology Services |
